PE20070997A1 - PYY AGONISTS AND IN THE TREATMENT OF OBESITY - Google Patents

PYY AGONISTS AND IN THE TREATMENT OF OBESITY

Info

Publication number
PE20070997A1
PE20070997A1 PE2006000929A PE2006000929A PE20070997A1 PE 20070997 A1 PE20070997 A1 PE 20070997A1 PE 2006000929 A PE2006000929 A PE 2006000929A PE 2006000929 A PE2006000929 A PE 2006000929A PE 20070997 A1 PE20070997 A1 PE 20070997A1
Authority
PE
Peru
Prior art keywords
obesity
treatment
conjugate
pyy agonists
pharmaceuitally
Prior art date
Application number
PE2006000929A
Other languages
Spanish (es)
Inventor
Rory Francis Finn
Nancy Ann Nardone
Ned Roger Siegel
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW095103474A external-priority patent/TWI310038B/en
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20070997A1 publication Critical patent/PE20070997A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) CONJUGADO mPEG DE FORMULA 4, DONDE n ES UN NUMERO ENTERO DE 250-295; -SR ES EL POLIPEPTIDO SELECCIONADO DE LA SEQ ID N:3 Y S ES EL GRUPO TIOL DE LA CISTEINA. EL RESTO DE (OCH2CH2)n TIENE UN PESO MOLECULAR MEDIO PONDERAL DE APROXIMADAMENTE 12kD; B) UN AGENTE ANTIOBESIDAD Y UN VEHICULO FARMACEUITCAMENTE ACEPTABLE. DICHO CONJUGADO ES AGONISTA DEL RECEPTOR Y2 DEL NEUROPEPTIDO Y (NPY), UTILES EN EL TRATAMIENTO DE OBESIDAD O SOBREPESOREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING: A) mPEG CONJUGATE OF FORMULA 4, WHERE n IS AN INTEGRAL NUMBER OF 250-295; -SR IS THE SELECTED POLYPEPTIDE FROM SEQ ID N: 3 AND S IS THE THIOL GROUP OF CYSTEINE. THE REST OF (OCH2CH2) n HAS A PONDERAL MEAN MOLECULAR WEIGHT OF APPROXIMATELY 12kD; B) AN ANTIOBESITY AGENT AND A PHARMACEUITALLY ACCEPTABLE VEHICLE. SAID CONJUGATE IS AGONIST OF THE Y2 RECEPTOR OF THE NEUROPEPTIDE Y (NPY), USEFUL IN THE TREATMENT OF OBESITY OR OVERWEIGHT

PE2006000929A 2006-01-27 2006-08-01 PYY AGONISTS AND IN THE TREATMENT OF OBESITY PE20070997A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TW095103474A TWI310038B (en) 2005-02-04 2006-01-27 Pyy agonists and uses thereof
CL2006000186 2006-01-27
PCT/IB2006/000270 WO2006082517A1 (en) 2005-02-04 2006-01-30 Pyy agonists and uses thereof

Publications (1)

Publication Number Publication Date
PE20070997A1 true PE20070997A1 (en) 2007-11-30

Family

ID=46969902

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000929A PE20070997A1 (en) 2006-01-27 2006-08-01 PYY AGONISTS AND IN THE TREATMENT OF OBESITY

Country Status (7)

Country Link
AR (1) AR054602A1 (en)
HN (1) HN2006027890A (en)
NL (1) NL1032266C2 (en)
PE (1) PE20070997A1 (en)
SV (1) SV2006002635A (en)
UY (1) UY29711A1 (en)
WO (1) WO2007085887A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
AU2006324076A1 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60230818D1 (en) * 2001-09-24 2009-02-26 Imp Innovations Ltd PYY3-36 FOR REDUCING OR PREVENTING GREASE LUBRICITY
US20070027073A1 (en) * 2003-04-08 2007-02-01 Menachem Rubinstein Long-acting derivatives of pyy agonists
PA8660701A1 (en) * 2005-02-04 2006-09-22 Pfizer Prod Inc SMALL AGONISTS AND THEIR USES
WO2006091505A2 (en) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists

Also Published As

Publication number Publication date
AR054602A1 (en) 2007-06-27
WO2007085887A1 (en) 2007-08-02
HN2006027890A (en) 2010-06-09
NL1032266A1 (en) 2007-07-30
UY29711A1 (en) 2007-08-31
NL1032266C2 (en) 2007-10-09
SV2006002635A (en) 2010-02-04

Similar Documents

Publication Publication Date Title
ES2558330T3 (en) Peptide WT1 restricted by HLA-A * 3303 and pharmaceutical composition comprising the same
DOP2006000025A (en) SMALL AGONISTS AND THEIR USES
PE20060880A1 (en) CONJUGATES OF POLYPEPTIDE AND A PENTASCARID HAVE IMPROVED PHARMACOKINETIC PROPERTIES
ECSP088239A (en) COMPOSITION OF SUSTAINED DRUG RELEASE
CL2009000171A1 (en) Compounds derived from 1-oxa-3-azaspiro, antagonists of the neuropeptide y5 receptor y (npy); pharmaceutical composition comprising said compound; and use for the treatment of eating disorders, drinking disorders, obesity, and depression.
CL2007003697A1 (en) COMPOUNDS DERIVED FROM SULFONAMIDE; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF HYPERGLUCEMIA, DIABETES, OBESITY, HYPERTENSION, HYPERLIPIDEMIA, METABOL SYNDROME
CL2008000863A1 (en) Compounds derived from 9-pyrimidin-4-yl-1-oxa-3,9-diaza-spiro (5.5) undecan-2-one; pharmaceutical composition containing said compounds; and its use to treat or prevent HIV infection, rheumatoid arthritis, asthma, congestive obstructive pulmonary disease and rejection of solid organ transplants.
CL2012002521A1 (en) Pharmaceutical composition comprising a dpp iv inhibitor selected from a defined group, a first diluent, a second diluent: mannitol, a second diluent: pregelatinized starch, a binder and a lubricant; Useful in the treatment of diabetes. (divisional of the sun. 1260-07).
AR071959A1 (en) DERIVATIVE OF BENZENE OR THIOPHEN AND ITS USE AS A VAP-1 INHIBITOR
CL2010001146A1 (en) Recombinant protein of porcine circovirus type 2 (pcv2); use of recombinant protein to prevent infection by pcv2; a package comprising the immunogenic composition (div exp 3475-2005).
BRPI0500704A (en) rehydratable personal care compositions
CL2011002453A1 (en) Compounds derived from diazol or oxazol-pyrrole or substituted condensed pyrrolcyclopropyl, inhibitors of the function of the ns5a protein encoded by the hepatitis c virus (vhc); pharmaceutical composition; and its use for the treatment of a vhc infection.
DE602006010564D1 (en) PYRIDOÄ2,3-DÜPYRIMIDIN-2,4-DIAMINE COMPOUNDS AS PTPIB INHIBITORS
CL2004000930A1 (en) COMPOUND DERIVED FROM DEFINED FORMULA DIHYDROQUINAZOLINE, USEFUL FOR THE TREATMENT AND / OR PROFILAXIS OF VIRAL INFECTIONS; PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMPOUND AND USE OF THE COMPOUND IN THE PREPARATION OF MEDICINES.
BR0108238A (en) Cosmetic compositions containing at least one hetero polymer and at least one film-forming silicone resin and methods of employing them
CL2008001005A1 (en) COMPOUNDS DERIVED FROM SULFUR, INHIBITORS OF THE SERINA PROTEASA NS3 OF THE VIRUS OF HEPATITIS C; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF ASSOCIATED DISORDERS TO HCV PROTEASE.
BRPI0509053A (en) anhydrous pharmaceutical composition and use of a silicon agent and a
UY30778A1 (en) COMPOUNDS OF 5,6-DIHIDRO-1H-PIRIDIN-2-ONA
ATE479440T1 (en) PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) SYNDROME VIRUS STRAINS AND COMPOSITIONS OF SWINE
WO2006076065A3 (en) Personal care compositions
CY1113115T1 (en) Peptides - HIV Fusion Inhibitors with Enhanced Biological Properties
BR0312173A (en) Recombinant cdna molecule, molecule and sequence, vector, process for preparing infectious measles virus particles, immunogenic composition, vaccine composition, and recombinant mononegaviral virus
ATE484505T1 (en) 5-SULFANYLMETHYLÄ1,2,4ÜTRIAZOLÄ1,5-AUPYRIMIDINE- - OLDERIVATES AS CXCR2 ANTAGONISTS
RS50550B (en) Pharmaceutical compositions from beard lichen (usnea barbata) and st.john's wort (hzpericum perforatum) and their use
CY1113824T1 (en) INTENSIVE COMPOSITIONS

Legal Events

Date Code Title Description
FC Refusal